1 |
Lee H, Yun KW, Lee HJ, Choi EH. Antimicrobial therapy of macrolideresistant Mycoplasma pneumoniae pneumonia in children. Expert Rev Anti Infect Ther 2018;16:23-34.
DOI
|
2 |
Hegde S, Hegde S, Spergser J, Brunthaler R, Rosengarten R, Chopra-Dewasthaly R. In vitro and in vivo cell invasion and systemic spreading of Mycoplasma agalactiae in the sheep infection model. Int J Med Microbiol 2014;304:1024-31.
DOI
|
3 |
Lee KY. Pneumonia, acute respiratory distress syndrome, and early immune-modulator therapy. Int J Mol Sci 2017;18:388.
DOI
|
4 |
Yang HJ. Benefits and risks of therapeutic alternatives for macrolide resistant Mycoplasma pneumoniae pneumonia in children. Korean J Pediatr 2019;62:199-205.
DOI
|
5 |
Yang EA, Kang HM, Rhim JW, Kang JH, Lee KY. Early corticosteroid therapy for Mycoplasma pneumoniae pneumonia irrespective of used antibiotics in children. J Clin Med 2019;8:726.
DOI
|
6 |
Saraya T. The history of Mycoplasma pneumoniae pneumonia. Front Microbiol 2016;7:364.
DOI
|
7 |
McCracken GH Jr. Current status of antibiotic treatment for Mycoplasma pneumoniae infections. Pediatr Infect Dis 1986;5:167-71.
DOI
|
8 |
Lee KY. Pediatric respiratory infections by Mycoplasma pneumoniae. Expert Rev Anti Infect Ther 2008;6:509-21.
DOI
|
9 |
Gardiner SJ, Gavranich JB, Chang AB. Antibiotics for community-acquired lower respiratory tract infections secondary to Mycoplasma pneumoniae in children. Cochrane Database Syst Rev 2015;1:CD004875.
|
10 |
Okada T, Morozumi M, Tajima T, Hasegawa M, Sakata H, Ohnari S, et al. Rapid effectiveness of minocycline or doxycycline against macrolideresistant Mycoplasma pneumoniae infection in a 2011 outbreak among Japanese children. Clin Infect Dis 2012;55:1642-9.
DOI
|